Although mAbs have been used in the treatment of cancer for more than 30 years, ongoing in the understanding of cancer biology and the emergence of next-generation sequencing technologies have accelerated the identification of molecular drivers of cancer and the search for antibody-based agents to block them.
This whitepaper identifies the key challenges faced at each stage of mAb development and provides guidance for streamlining pipeline progress of therapeutic mAb candidates, focusing specifically on the following: